Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany).Mathias Rummel, Wolfram Brugger, Manfred Welslau et al.|Blood|2009Cited by 157
Bendamustine Plus Rituximab Versus CHOP Plus Rituximab in the First-Line Treatment of Patients with Indolent and Mantle Cell Lymphomas - First Interim Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany).Mathias Rummel, Ulrich von Gruenhagen, N. Niederle et al.|Blood|2007Cited by 65
Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study.Mathias Rummel, N. Niederle, Georg Maschmeyer et al.|Journal of Clinical Oncology|2012Cited by 50
Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study.Mathias Rummel, N. Niederle, Georg Maschmeyer et al.|Journal of Clinical Oncology|2012Cited by 39
Efficacy and safety of bendamustine and rituximab in the treatment of indolent and mantle cell lymphomas in older patientsMathias Rummel, Ulrich Kaiser, K. Heine et al.|Journal of Clinical Oncology|2008Cited by 15